MigraineMind research summary
Long-term neuromuscular alterations during botulinum toxin treatment for chronic migraine.
Clin Neurophysiol Pract | 2026
Clinical trialSummary
This study examined the effects of botulinum toxin type A on chronic migraine. Forty women with chronic migraine received varying lengths of BoNTA treatment. Researchers evaluated migraine frequency, pain burden, and quality of life. They also conducted neurophysiological assessments, including nerve conduction studies and EMG. The results showed that BoNTA significantly reduced migraine days. This reduction was consistent across all treatment groups. However, 75% of patients reported neuromuscular side effects after one year. Common side effects included ptosis, diplopia, and shoulder weakness. In treatment-naïve patients, significant declines in frontalis CMAP amplitudes occurred by week 12. Long-term patients showed the most pronounced changes in the trapezius muscle. Up to 60% of patients exhibited spontaneous activity consistent with denervation. Abnormal jitter was found in 47% of participants. Overall, these findings highlight persistent neuromuscular alterations needing careful monitoring during treatment. Clinical relevance: This research highlights the importance of monitoring neuromuscular side effects during long-term botulinum toxin treatment for chronic migraine.
Key Learning Points
- Botulinum toxin type A significantly reduces the number of days patients experience migraines.
- Most patients treated with botulinum toxin type A report neuromuscular side effects after one year.
- Common side effects include drooping eyelids, double vision, and weakness in the shoulder area.
- Patients who have been treated for a longer time show more pronounced changes in muscle function.
- Monitoring for neuromuscular alterations is essential during long-term botulinum toxin treatment for chronic migraine.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.